Knowledge Gaps and Nonadherence Among Japanese Patients with Atherosclerotic Cardiovascular Disease
Abstract
AIM: Reducing low-density lipoprotein cholesterol (LDL-C) levels is crucial for preventing atherosclerotic cardiovascular disease (ASCVD). Recommended lipid-lowering therapy (LLT) includes both oral (e.g., statins) and injectable agents. However, patient awareness of LDL-C management and adherence to it remain uncertain. METHODS: This cross-sectional study surveyed 415 Japanese patients with ASCVD using a web-based platform. The participants reported their understanding of LDL-C target values and the effects of LLT. Medication adherence was evaluated using the Extent of Nonadherence scale, and a binomial logistic regression analysis was performed to identify the factors associated with nonadherence. RESULTS: Approximately 58.1%-60.2% of the participants reported confidence in knowing their correct lipid target values and managing dyslipidemia appropriately. However, only 22.2% reported LDL-C targets of ＜50 or ＜70 mg/dL, and 43.4% believed their targets to be ＜50, ＜70, or ＜100 mg/dL. In contrast, 56.7% either reported LDL-C targets of ＜120, ＜140, or ＜160 mg/dL or did not know their targets. Regarding LLT, 65.8% were unaware that extreme lowering of LDL-C levels with LLT had no disadvantages, and 74.2% were unaware that injectable LLTs were available. Overall, 39.0% of the participants were nonadherent. Higher out-of-pocket costs (≥ 3,001 yen; adjusted odds ratio [OR]: 1.83, p = 0.024) and experience with self-injections (adjusted odds ratio: 2.34, p = 0.027) were significantly associated with nonadherence. CONCLUSIONS: Our findings highlight a considerable gap in patient knowledge and adherence to dyslipidemia management strategies. Interventions that promote patient education and shared decision-making are essential for improving adherence and achieving optimal LDL-C targets.
Related
- Trends and Factors Associated with LDL-C Treatment Target Attainment Rates among Patients with Secondary Prevention Setting of Atherosclerotic Cardiovascular Disease: Assessments from Japanese Health Checkup Data
- Expectations for Angiopoietin-like 3 Inhibitors Taking Broad Lipid-modifying Effects on the Comprehensive Control of Atherosclerotic Cardiovascular Disease Risk in Patients with Homozygous Familial Hypercholesterolemia
- Economic evaluation of SGLT2 inhibitors and GLP-1 receptor agonists in Thai patients with type 2 diabetes and established atherosclerotic cardiovascular disease
- Cardiometabolic risk factors and Mediterranean diet adherence in patients with premature atherosclerotic cardiovascular disease in Iran
- Residual atherosclerotic cardiovascular disease risk in statin-treated patients: mechanisms, therapeutic strategies, and future directions—a scoping review
BibTeX
@article{toda2026knowledge,
title = {{Knowledge Gaps and Nonadherence Among Japanese Patients with Atherosclerotic Cardiovascular Disease}},
author = {Mitsutoshi Toda and Kazuma Iekushi and Yuri Takahashi and Shun Kohsaka},
journal = {Journal of Atherosclerosis and Thrombosis},
year = {2026},
month = jul,
doi = {10.5551/jat.66074},
url = {https://www.jstage.jst.go.jp/article/jat/advpub/0/advpub_66074/_article},
note = {CC BY-NC-SA},
}
RIS
TY - JOUR
TI - Knowledge Gaps and Nonadherence Among Japanese Patients with Atherosclerotic Cardiovascular Disease
AU - Mitsutoshi Toda
AU - Kazuma Iekushi
AU - Yuri Takahashi
AU - Shun Kohsaka
PY - 2026
DA - 2026/07/02
JO - Journal of Atherosclerosis and Thrombosis
DO - 10.5551/jat.66074
UR - https://www.jstage.jst.go.jp/article/jat/advpub/0/advpub_66074/_article
AB - AIM: Reducing low-density lipoprotein cholesterol (LDL-C) levels is crucial for preventing atherosclerotic cardiovascular disease (ASCVD). Recommended lipid-lowering therapy (LLT) includes both oral (e.g., statins) and injectable agents. However, patient awareness of LDL-C management and adherence to it remain uncertain. METHODS: This cross-sectional study surveyed 415 Japanese patients with ASCVD using a web-based platform. The participants reported their understanding of LDL-C target values and the effects of LLT. Medication adherence was evaluated using the Extent of Nonadherence scale, and a binomial logistic regression analysis was performed to identify the factors associated with nonadherence. RESULTS: Approximately 58.1%-60.2% of the participants reported confidence in knowing their correct lipid target values and managing dyslipidemia appropriately. However, only 22.2% reported LDL-C targets of ＜50 or ＜70 mg/dL, and 43.4% believed their targets to be ＜50, ＜70, or ＜100 mg/dL. In contrast, 56.7% either reported LDL-C targets of ＜120, ＜140, or ＜160 mg/dL or did not know their targets. Regarding LLT, 65.8% were unaware that extreme lowering of LDL-C levels with LLT had no disadvantages, and 74.2% were unaware that injectable LLTs were available. Overall, 39.0% of the participants were nonadherent. Higher out-of-pocket costs (≥ 3,001 yen; adjusted odds ratio [OR]: 1.83, p = 0.024) and experience with self-injections (adjusted odds ratio: 2.34, p = 0.027) were significantly associated with nonadherence. CONCLUSIONS: Our findings highlight a considerable gap in patient knowledge and adherence to dyslipidemia management strategies. Interventions that promote patient education and shared decision-making are essential for improving adherence and achieving optimal LDL-C targets.
SN - 1880-3873
SN - 1340-3478
ER -